{"disease":{"id":"maintenance-therapy","name":"maintenance therapy"},"drugs":{"marketed":[{"drug_id":"avelumab","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"thalidomide","indication_name":"Maintenance Therapy for ENL Recurrence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."},{"drug_id":"nizatidine","indication_name":"Maintenance Therapy for Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"flovent-500mcg","indication_name":"Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLOVENT 500mcg","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor (GR)","drug_class":"Inhaled corticosteroid (ICS)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bavencio","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07463651","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06622798","title":"Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06277050","title":"Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":264,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT07014189","title":"Nevirapine / Lamivudine for HIV Maintenance Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Cantonal Hospital of St. Gallen","has_results":false},{"nct_id":"NCT03160105","title":"Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Calmy Alexandra","has_results":false},{"nct_id":"NCT05869227","title":"Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"XIANG YANQUN","has_results":false},{"nct_id":"NCT04737343","title":"Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":114,"lead_sponsor_name":"Chinese SLE Treatment And Research Group","has_results":false},{"nct_id":"NCT03384342","title":"Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Catholic University of Korea","has_results":false},{"nct_id":"NCT03384459","title":"Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Catholic University of Korea","has_results":false},{"nct_id":"NCT07101497","title":"Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06888037","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04552912","title":"Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05170542","title":"The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05965284","title":"Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Chinese SLE Treatment And Research Group","has_results":false},{"nct_id":"NCT06207799","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01872026","title":"Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}